title: [Value of the new anticonvulsants in pediatrics].
abstract: Within the last years five new antiepileptics have become available in Germany. Vigabatrin is a second choice drug against partial seizures, West syndrome and epilepsies in infant encephalopathy syndromes. Lamotrigine and Gabapentin can be used as add-on therapy in partial seizures in children above 12 years of age Felbamate has a high incidence of severe side-effects like aplastic anemia and liver failure. Therefore it should be restricted to the treatment of Lennox-Gastaut syndrome. Oxcarbazepine is not yet on the German market, but is available by import from Austria. Its therapeutic range is similar to carbamazepine with less side-effects. The new antiepileptics discussed have turned out to be useful additional therapeutics, especially in focal epilepsies. There is, however, still limited experience with these drugs in children. So none can as yet be considered a drug of first choice in any epileptic childhood disorder. The classical antiepileptic drugs remain essential in antiepileptic therapy.
authors.affiliation: Abteilung für Neuropädiatrie und Stoffwechselerkrankungen, Universitäts-Kinderklinik Marburg.
authors.forename: M
authors.initials: M
authors.lastname: Köhler
authors.forename: G F
authors.initials: GF
authors.lastname: Hoffmann
mesh_terms: D000293:Adolescent; D016907:Adverse Drug Reaction Reporting Systems; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D017277:Drug Approval; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007223:Infant
chemical_list: D000927:Anticonvulsants
vernacular_title: Stellenwert der neuen Antiepileptika in der Pädiatrie.